Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
MEDIPAN GmbH
Ludwig-Erhard-Ring 3,
15827
Blankenfelde-Mahlow
Germany
Germany
Telephone +49 33708 44170
Fax +49 33708 441725
info@medipan.de
http://www.medipan.de Visit our booth at medica.diagnostiknet-bb.de
Fax +49 33708 441725
info@medipan.de
http://www.medipan.de Visit our booth at medica.diagnostiknet-bb.de
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
This company is co-exhibitor of
DiagnostikNet-BB
Contact
Prof. Dr. Dirk Roggenbuck
CEO MEDIPAN GmbH
Dr. Matthias Stephan
Head of Sales and Marketing
Selma Balci
International Sales Manager Middle East / Europe
Anna Mashirova
International Sales Manager Eastern Europe
Our range of products
Product categories
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.01 Immuno assay testing
Immuno assay testing
- Anti-Phospholipid 10 Dot - Profiling immunoassay for the determination antibodies to 10 phospholipids and serum proteins
- Anti-Ganglioside 12 LINE - Profile Diagnostics (IgG/IgM) - For diagnosis and therapeutically relevant information of peripheral polyneuropathies
- GA CoV-2 IgG/IgM/IgG+ - ELISA kits for COVID-19 diagnostics
- Anti-GP2 ELISA - Quantitative assay for the determination of antibodies to glycoprotein 2 (GP-2) for the diagnosis of Crohn’s disease.
- SELco® TRAb human 1 step - One step Radioimmunoassay for the diagnosis of autoimmune thyroid diseases
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.04 Other equipment for immunochemistry and immunology
Other equipment for immunochemistry and immunology
Our products
Product category: Other equipment for immunochemistry and immunology
DotDiver2.0 - The first fully automated System for Dot / Line Assays
The DotDiver2.0 is a fully automated processor of Line and Dot immunoassays.
The small footprint renders the device as an ideal solution for laboratories with limited space. With an unique software design, the device provides a completely hands-free experience for quantitative and semi-quantitative testing via repeated diving of the antigen coated strips into the ready to use cartridges.
This special setup provides an optimal reaction environment with reduced assay processing and result analysis time for up to 24 different tests simultaneously.
A wide range of immunoassays available for the DotDiver2.0 opens the world of diagnosis of autoimmune diseases, especially systemic inflammatory rheumatic diseases, autoimmune gastroenterology, neuropathies, anti-phospholipid syndrome, vasculitis, nephritis, myositis, scleroderma and autoimmune hepatitis.
DotDiver 2.0 helps to simplify modern diagnostics in both time and cost effective manners for optimal processing in medical laboratories with high sample volumes.
The small footprint renders the device as an ideal solution for laboratories with limited space. With an unique software design, the device provides a completely hands-free experience for quantitative and semi-quantitative testing via repeated diving of the antigen coated strips into the ready to use cartridges.
This special setup provides an optimal reaction environment with reduced assay processing and result analysis time for up to 24 different tests simultaneously.
A wide range of immunoassays available for the DotDiver2.0 opens the world of diagnosis of autoimmune diseases, especially systemic inflammatory rheumatic diseases, autoimmune gastroenterology, neuropathies, anti-phospholipid syndrome, vasculitis, nephritis, myositis, scleroderma and autoimmune hepatitis.
DotDiver 2.0 helps to simplify modern diagnostics in both time and cost effective manners for optimal processing in medical laboratories with high sample volumes.
Product category: Other equipment for immunochemistry and immunology
AKLIDES® - 1st Fully automated digital IFA System
The AKLIDES® technology was the first automated system for the immunofluorescence (IF) standardization in routine laboratories for autoimmunity. Today AKLIDES® is also applicable in the field of cell damage and microbiology.
Main features of the automated system are:
Analysis
Analysis of fluorescence patterns and quantification of fluorescence intensities is provided by AKLIDES®. The system offers a standardized positive-negative decision and pattern recognition in less than 30 seconds per well. Assays for ANA, ANCA, nDNA, tissues and CytoBead® are available with fully automated analysis.
Image Storage
AKLIDES® automatically stores the fluorescence images and defined patterns of each sample. This allows digital archiving over years and searching for results in an internal database.
Intensity Calibration
The AKLIDES® calibration slides are characterized by stable fluorescence for years. Yearly calibration leads to an even better standardization.
Titer Detection
Due to the AKLIDES® titer detection algorithm titration of patient samples for the cell-based assays is no longer needed. The AKLIDES® Doctor software allows access to the AKLIDES® analysis data from every work space. With the appropriate network structure, working via internet is also possible.
Export Options
AKLIDES® can generate an overall report of all relevant quantitative results in pdf- and csv-format and/or a single well report in pdf-format (including cell images). This allows the laboratory to seek instrument independent expert opinion worldwide by sending the reports by e-mail. Furthermore connecting to LIMS is also possible.
Modular Software Design
The AKLIDES® software is the key component of the system. The software guarantees optimal image processing and fully automated analysis of immunofluorescence signals using intelligent image processing algorithms. The modular design allows to upgrade the software licenses needed.
Main features of the automated system are:
Analysis
Analysis of fluorescence patterns and quantification of fluorescence intensities is provided by AKLIDES®. The system offers a standardized positive-negative decision and pattern recognition in less than 30 seconds per well. Assays for ANA, ANCA, nDNA, tissues and CytoBead® are available with fully automated analysis.
Image Storage
AKLIDES® automatically stores the fluorescence images and defined patterns of each sample. This allows digital archiving over years and searching for results in an internal database.
Intensity Calibration
The AKLIDES® calibration slides are characterized by stable fluorescence for years. Yearly calibration leads to an even better standardization.
Titer Detection
Due to the AKLIDES® titer detection algorithm titration of patient samples for the cell-based assays is no longer needed. The AKLIDES® Doctor software allows access to the AKLIDES® analysis data from every work space. With the appropriate network structure, working via internet is also possible.
Export Options
AKLIDES® can generate an overall report of all relevant quantitative results in pdf- and csv-format and/or a single well report in pdf-format (including cell images). This allows the laboratory to seek instrument independent expert opinion worldwide by sending the reports by e-mail. Furthermore connecting to LIMS is also possible.
Modular Software Design
The AKLIDES® software is the key component of the system. The software guarantees optimal image processing and fully automated analysis of immunofluorescence signals using intelligent image processing algorithms. The modular design allows to upgrade the software licenses needed.
Product category: Other equipment for immunochemistry and immunology
akiron®NEO - Small and Fast System for IFA Automation
akiron®NEO is a fully automated and standardized imaging and data processing IFA system used in the diagnosis of autoimmune diseases.
akiron®NEO is the small succesor version of akiron®, a fully automated and standardized imaging and data processing system of immunofluorescence assays for the diagnosis of autoimmune diseases. An easily operated imager that provides high quality results in a short period, akiron®NEO proves its worth every day in the lab, especially for all those with a limited labspace.
Applications of the akiron®NEO can be found in the field of immunology like all traditional tests for the detection of autoantibodies as HEp-2 cells (ANA) and granulocytes (ANCA). Tissues (several antibodies) can be analyzed as well.
Features:
akiron®NEO is the small succesor version of akiron®, a fully automated and standardized imaging and data processing system of immunofluorescence assays for the diagnosis of autoimmune diseases. An easily operated imager that provides high quality results in a short period, akiron®NEO proves its worth every day in the lab, especially for all those with a limited labspace.
Applications of the akiron®NEO can be found in the field of immunology like all traditional tests for the detection of autoantibodies as HEp-2 cells (ANA) and granulocytes (ANCA). Tissues (several antibodies) can be analyzed as well.
Features:
- Fully automated screening and objective pattern and intensity evaluation of cells (ANA and ANCA) in about 30 seconds
- Easily operated by touchscreen
- Digital archiving of fluorescence images and results (data management included)
- Antibodies quantification [U/ml or IU/ml] with lot specific standard curves using 4-point calibration
- Automated titer detection based on the screening dilution (ANA and ANCA)
- Documentation of tissue sections via overview images
- Standardized and reliable results between different instruments due to intensity calibration
- Overall report of all relevant quantitative results in pdf- and xls-formats
- Single well report in pdf-format (including cell images)
- LIMS Connectivity
Product category: Other equipment for immunochemistry and immunology
akiron® - Fully automated digital IFA System
The akiron® is the smaller version of the AKLIDES® system, for the fully automated and standardized imaging and data processing of IFA.
Applications for the akiron® are in the field of immunology. On the one hand traditional tests for the detection of autoantibodies like HEp-2 cells (ANA), granulocytes (ANCA) and tissues (several antibodies) can be analysed with this system. On the other hand it is characterized through the revolutionary CytoBead® technology for ANA, ANCA, RPGN and celiac disease diagnosis.
High qualitative, easy to operate with universal applications, akiron® proves its worth every day in the laboratory.
The main features are:
Applications for the akiron® are in the field of immunology. On the one hand traditional tests for the detection of autoantibodies like HEp-2 cells (ANA), granulocytes (ANCA) and tissues (several antibodies) can be analysed with this system. On the other hand it is characterized through the revolutionary CytoBead® technology for ANA, ANCA, RPGN and celiac disease diagnosis.
High qualitative, easy to operate with universal applications, akiron® proves its worth every day in the laboratory.
The main features are:
- Fully automated screening and objective pattern and intensity evaluation of cells (ANA and ANCA) in about 30 seconds
- Automated microbead identification and measurement of the ligand fluorescence intensity of the beads (CytoBead® assays)
- Quantification of antibodies in U/ml or IU/ml with lot specific standard curves using the microbeads (4-point calibration)
- Automated titer detection based on the screening dilution (ANA and ANCA)
- Documentation of tissue sections via overview images
- Standardized and reliable results between different instruments due to intensity calibration
- Overall report of all relevant quantitative results in pdf- and xls-format
- Single well report in pdf-format (including cell images)
- Data transfer from pipetting robot AKENOMI® possible using LIMS
- Access to the data from every work place with doctor software
- Digital archiving of fluorescence images and results allows searching of results even after years
Product category: Other equipment for immunochemistry and immunology
AKENOMI®NEO - A highly flexible IFA pipettor
The AKENOMI®NEO is a compact and highly flexible IFA pipettor providing cost-effective automation of your IFA assays.
COMPACT DESIGN
Although small, the AKENOMI®NEO boasts of an impressive capacity, helping you to maximize the use of your limited bench space. It processes batches of up to 64 samples and 12 IFA slides.
EASY TO SET UP
The AKENOMI®NEO IFA Application Software has been designed to be
easy to program. All assay parameters are entered by means of a simple spreadsheet interface with instant online help available for each parameter.
FLEXIBLE APPLICATIONS
The AKENOMI®NEO software caters for a wide variety of IFA applications. "CCX-IFA", the protocol and worklist generator, enables you to define protocols combining up to 12 different IFA assays. Each assay is independently programmable, allowing you to control all liquid handling parameters.
INFORMATIVE WORKLISTS
Having defined a protocol, routine operation simply requires you to define a worklist in which the test requests for each sample are entered. Controls can be presented to the AKENOMI®NEO either ready diluted or undiluted.
COMPACT DESIGN
Although small, the AKENOMI®NEO boasts of an impressive capacity, helping you to maximize the use of your limited bench space. It processes batches of up to 64 samples and 12 IFA slides.
EASY TO SET UP
The AKENOMI®NEO IFA Application Software has been designed to be
easy to program. All assay parameters are entered by means of a simple spreadsheet interface with instant online help available for each parameter.
FLEXIBLE APPLICATIONS
The AKENOMI®NEO software caters for a wide variety of IFA applications. "CCX-IFA", the protocol and worklist generator, enables you to define protocols combining up to 12 different IFA assays. Each assay is independently programmable, allowing you to control all liquid handling parameters.
INFORMATIVE WORKLISTS
Having defined a protocol, routine operation simply requires you to define a worklist in which the test requests for each sample are entered. Controls can be presented to the AKENOMI®NEO either ready diluted or undiluted.
Product category: Immuno assay testing
Anti-Phospholipid 10 Dot - Profiling immunoassay for the determination antibodies to 10 phospholipids and serum proteins
Laboratory diagnosis criteria of anti-phospholipid antibody syndrome (APS or APLS) includes the detection of lupus anticoagulant as well as antibodies against cardiolipin and/or β2-glycoprotein I, and remain challenging since APS antibodies can be associated with several infections.
The immunoassay Anti-Phospholipid 10 Dot offers for the first time the possibility to profile APS antibodies detection in serum, along with the criteria antigens cardiolipin and β2‑glycoprotein I, also other non-criteria 6 phospholipids and 1 additional serum protein.
In contrast to commercially available ELISA Kits, the Anti-Phospholipid 10 Dot due to its optimal orientation of the antigens allow the correct binding of patient plasma protein cofactors, e.g. β 2 glycoprotein-I (β2 GP-I), leading to exposure of the specific epitope for the APS related antibodies.
The large number of antigens and the optimal exposure of the epitope contribute to a high specificity in diagnosis of APS, better subtyping and easier differential diagnosis of APS patients.
The test gives reliable results in serum in less than 2h and can be run easily manually or completely automated using a DotDiver2.0.
APS, also known as Hughes syndrome, is an autoimmune disease in which antiphospholipid antibodies react against proteins that bind to anionic phospholipids on plasma membranes. The clinical symptoms include arterial and venous thrombosis, thrombocytopenia and recurrent fetal loss; stillbirth, preterm delivery, and severe preeclampsia.
APS can be primary, in which case the autoimmunity occurs in the absence of other related diseases; or secondary APS, which occurs in combination with other autoimmune diseases, such as systemic lupus erythematosus (SLE). On rare occasions, APS may lead to rapid organ failure due to generalized thrombosis, termed "catastrophic antiphospholipid syndrome" (CAPS or Asherson syndrome) which is associated with a high risk of death.
The immunoassay Anti-Phospholipid 10 Dot offers for the first time the possibility to profile APS antibodies detection in serum, along with the criteria antigens cardiolipin and β2‑glycoprotein I, also other non-criteria 6 phospholipids and 1 additional serum protein.
In contrast to commercially available ELISA Kits, the Anti-Phospholipid 10 Dot due to its optimal orientation of the antigens allow the correct binding of patient plasma protein cofactors, e.g. β 2 glycoprotein-I (β2 GP-I), leading to exposure of the specific epitope for the APS related antibodies.
The large number of antigens and the optimal exposure of the epitope contribute to a high specificity in diagnosis of APS, better subtyping and easier differential diagnosis of APS patients.
The test gives reliable results in serum in less than 2h and can be run easily manually or completely automated using a DotDiver2.0.
APS, also known as Hughes syndrome, is an autoimmune disease in which antiphospholipid antibodies react against proteins that bind to anionic phospholipids on plasma membranes. The clinical symptoms include arterial and venous thrombosis, thrombocytopenia and recurrent fetal loss; stillbirth, preterm delivery, and severe preeclampsia.
APS can be primary, in which case the autoimmunity occurs in the absence of other related diseases; or secondary APS, which occurs in combination with other autoimmune diseases, such as systemic lupus erythematosus (SLE). On rare occasions, APS may lead to rapid organ failure due to generalized thrombosis, termed "catastrophic antiphospholipid syndrome" (CAPS or Asherson syndrome) which is associated with a high risk of death.
Product category: Immuno assay testing
Anti-Ganglioside 12 LINE - Profile Diagnostics (IgG/IgM) - For diagnosis and therapeutically relevant information of peripheral polyneuropathies
In the investigations of a peripheral neuropathy with a possible immunological background detection of antibodies against gangliosides is considered very important for the diagnosis, but also provides therapeutically relevant information regarding the subtype of neuropathic disease (i.e Guillain-Barré syndrome, Miller-Fisher syndrome and others).
Gangliosides are acidic glycolipids, comprised of a lipid (ceramide), an oligosaccharide chain and sialic acid. The Anti-Ganglioside 12 LINE is the ideal and efficient tool to support this important task, offering with 12 different antigens the possibility to have the largest patient profile in the market.
In contrast to commercially available ELISA, the Anti-Ganglioside 12 LINE due to its optimal orientation of the antigens, allows a binding of only specific antibodies to the disease relevant epitope.
The test gives reliable results in serum or cerebrospinal fluid (CSF) for 12 different anti-gangliside antibodies in short time and can be run easily manually or completely automated using a DotDiver2.0.
Inflammatory neuropathies of the peripheral nervous system are characterized by numerous clinical symptoms, which can range from mild fatigue and uncharacteristic discomfort to neuromuscular disorders and functional deficiencies, like respiratory failure and cardiac arrest.
Autoantibodies against gangliosides occur in autoimmune diseases of the peripheral nervous system. Gangliosides are components of cell membranes and are particularly found in the central and peripheral nervous system. These antibodies directly cause an inflammation or demyelinization of the myelin sheaths, therapy of autoimmune neuropathies is therefore based on immunoregulation.
Gangliosides are acidic glycolipids, comprised of a lipid (ceramide), an oligosaccharide chain and sialic acid. The Anti-Ganglioside 12 LINE is the ideal and efficient tool to support this important task, offering with 12 different antigens the possibility to have the largest patient profile in the market.
In contrast to commercially available ELISA, the Anti-Ganglioside 12 LINE due to its optimal orientation of the antigens, allows a binding of only specific antibodies to the disease relevant epitope.
The test gives reliable results in serum or cerebrospinal fluid (CSF) for 12 different anti-gangliside antibodies in short time and can be run easily manually or completely automated using a DotDiver2.0.
Inflammatory neuropathies of the peripheral nervous system are characterized by numerous clinical symptoms, which can range from mild fatigue and uncharacteristic discomfort to neuromuscular disorders and functional deficiencies, like respiratory failure and cardiac arrest.
Autoantibodies against gangliosides occur in autoimmune diseases of the peripheral nervous system. Gangliosides are components of cell membranes and are particularly found in the central and peripheral nervous system. These antibodies directly cause an inflammation or demyelinization of the myelin sheaths, therapy of autoimmune neuropathies is therefore based on immunoregulation.
Product category: Immuno assay testing
GA CoV-2 IgG/IgM/IgG+ - ELISA kits for COVID-19 diagnostics
Our GA CoV-2 IgG/IgM/IgG+ ELISA kits are serological tests (Enzyme Immunoassays) to identify virus-specific SARS-CoV-2 antibodies in patients. They are ideally suited for screening and subsequent confirmation of the antibody status in patients, in order to verify the individual immune protection, control the existing pandemic and reduce the spread of SARS-CoV-2 through targeted measures.
The GA CoV-2 IgG+ confirmatory test offers reliable support to differentiate other coronavirus infections and aids in the assessment of immune protection. Following a positive antibody result in screening, virus-specific antibodies against the N-, S1- and S2- proteins are determined using this confirmatory test.
Your advandages with our GA CoV-2 IgG/IgM/IgG+ ELISA kits:
GA CoV-2 IgG / IgM
A first study conducted in an emergency centre for COVID-19 infected patients showed outstanding sensitivities and specificities using the GA CoV-2 IgM/IgG/IgG+ ≥ 98%.
The GA CoV-2 IgG+ confirmatory test offers reliable support to differentiate other coronavirus infections and aids in the assessment of immune protection. Following a positive antibody result in screening, virus-specific antibodies against the N-, S1- and S2- proteins are determined using this confirmatory test.
Your advandages with our GA CoV-2 IgG/IgM/IgG+ ELISA kits:
GA CoV-2 IgG / IgM
- ELISA screening for the determination of IgG or IgM SARS-CoV-2 antibodies in serum and plasma
- 96 determinations per test kit including positive and negative controls
- 105 min total assay time
- 15 months shelf life
- Fully automatable
- CE marked
- 24x4 determinations per test kit including positive and negative controls
- 105 min total assay time
- 15 months shelf life
- Fully automatable
- CE marked
A first study conducted in an emergency centre for COVID-19 infected patients showed outstanding sensitivities and specificities using the GA CoV-2 IgM/IgG/IgG+ ≥ 98%.
Product category: Immuno assay testing
Anti-GP2 ELISA - Quantitative assay for the determination of antibodies to glycoprotein 2 (GP-2) for the diagnosis of Crohn’s disease.
Non-specific inflammatory bowel disease including Crohn’s disease (CD) (Enteritis regionalis) and ulcerative colitis (UC) are characterized by chronic-remitting inflammatory processes of the intestine.
GA Generic Assays Anti-GP2 ELISA determine antibodies to the major antigen of the exocrine pancreas, the membrane-bound pancreatic Glycoprotein 2 (GP2). Antibodies against GP2, in combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which is highly prevalent (70 %) in patients with CD and atypical antineutrophil cytoplasmatic antigens (aANCA), mainly found in patients with UC, could be used as a highly specific serological marker for differential diagnosis of CD to UC.
GA Generic Assays Anti-GP2 ELISA is used for the quantitative determination of IgA and IgG antibodies against glycoprotein 2 (GP2) in human serum.
Like all other GA Generic Assays’ ELISA assays, the Anti-GP2 ELISA can be implemented on all the most common open ELISA automation systems.
GA Generic Assays Anti-GP2 ELISA determine antibodies to the major antigen of the exocrine pancreas, the membrane-bound pancreatic Glycoprotein 2 (GP2). Antibodies against GP2, in combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which is highly prevalent (70 %) in patients with CD and atypical antineutrophil cytoplasmatic antigens (aANCA), mainly found in patients with UC, could be used as a highly specific serological marker for differential diagnosis of CD to UC.
GA Generic Assays Anti-GP2 ELISA is used for the quantitative determination of IgA and IgG antibodies against glycoprotein 2 (GP2) in human serum.
Like all other GA Generic Assays’ ELISA assays, the Anti-GP2 ELISA can be implemented on all the most common open ELISA automation systems.
Product category: Immuno assay testing
SELco® TRAb human 1 step - One step Radioimmunoassay for the diagnosis of autoimmune thyroid diseases
SELco® TRAb human 1 step is a sensitive radioimmunoassay for the detection of TSH receptor antibodies.
Compared to the classical two-step assay, the incubation time is shortened to 120 minutes in one step only.
Your advandtages at a glance:
SELco® TRAb human 1-step is a competitive radio receptor assay (RRA). During the incubation step the TSH receptor autoantibodies (TRAb) of the patient samples or calibrators compete with iodinated monoclonal antibodies (Tracer) to TSH receptor for the immobilized TSH receptor on the solid phase of coated tubes.
The level of the measuring signal is inversely proportional to the TRAb concentration in the tested samples and can be read off from a calibrator curve with known TRAb concentrations.
Scientific Background
Graves' disease is an autoimmune disease of the thyroid gland. In this disease the body's own defense cells form antibodies against receptors of the thyroid cells, resulting to increasinged production of thyroid hormones, known as hyperthyroidism. The consequences are numerous disorders, such as tachycardia or cardiac arrhythmia, weight loss amidst ravenous appetite, restlessness and nervousness.
The determination of the TSH receptor antibodies (TRAb) is a major step in the diagnosis of Graves' disease.
Compared to the classical two-step assay, the incubation time is shortened to 120 minutes in one step only.
Your advandtages at a glance:
- Only 120 minutes incubation time
- One step Assay
- Suitable for automated processing
- Calibration based on the international reference standard WHO-08/204 (2nd International Standard for Thyroid Stimulating Antibody)
SELco® TRAb human 1-step is a competitive radio receptor assay (RRA). During the incubation step the TSH receptor autoantibodies (TRAb) of the patient samples or calibrators compete with iodinated monoclonal antibodies (Tracer) to TSH receptor for the immobilized TSH receptor on the solid phase of coated tubes.
The level of the measuring signal is inversely proportional to the TRAb concentration in the tested samples and can be read off from a calibrator curve with known TRAb concentrations.
Scientific Background
Graves' disease is an autoimmune disease of the thyroid gland. In this disease the body's own defense cells form antibodies against receptors of the thyroid cells, resulting to increasinged production of thyroid hormones, known as hyperthyroidism. The consequences are numerous disorders, such as tachycardia or cardiac arrhythmia, weight loss amidst ravenous appetite, restlessness and nervousness.
The determination of the TSH receptor antibodies (TRAb) is a major step in the diagnosis of Graves' disease.
Product category: Diagnostic rapid tests
GA CoV-2 Antigen Rapid - Test for efficient SARS-CoV-2 acute diagnostics
The GA CoV-2 Antigen Rapid test from GA Generic Assays GmbH enables a reliable and timely diagnosis for patients with regards to a possible SARS-CoV-2 infection. The test is meant to be used to screen large numbers of people in a short time in order to reliably determine their infection status.
The GA CoV-2 Antigen Rapid test supports health professionals with a complete test kit, which enables the use independently at the point of care.
For all people who are suspected of having an acute SARS-CoV-2 infection.
Your advantages at a glance:
The GA CoV-2 Antigen Rapid test supports health professionals with a complete test kit, which enables the use independently at the point of care.
For all people who are suspected of having an acute SARS-CoV-2 infection.
Your advantages at a glance:
- Immediate test results after just 15 minutes
- Convincing performance data
- Sensitivity: 96.4% (95%CI: 89.8% - 99.2%)
- Specificity: 99.2% (95%CI: 95.5% - 99.9%)
- Universal field of application at the point of care
- Fast and reliable test realization even with large case numbers
- Complete test kit for professional use
About us
Company details
MEDIPAN GmbH is a leading company in the development, manufacturing and marketing of IVD kits and instruments.
Together with its sister company GA Generic Assays, MEDIPAN has got an extensive experience in immunochemistry and biomedicine, especially in tissue and cell-based IFA, ELISA, Dot/LINE assays for the diagnosis of rheumatic and other autoimmune diseases with neurologic, vascular, hepatic, renal or gastrointestinal origin.
MEDIPAN is a continuously growing company in the diagnostic market looking for innovative research and distribution partners worldwide to strengthen our existing network of partners and customers.
Together with its sister company GA Generic Assays, MEDIPAN has got an extensive experience in immunochemistry and biomedicine, especially in tissue and cell-based IFA, ELISA, Dot/LINE assays for the diagnosis of rheumatic and other autoimmune diseases with neurologic, vascular, hepatic, renal or gastrointestinal origin.
MEDIPAN is a continuously growing company in the diagnostic market looking for innovative research and distribution partners worldwide to strengthen our existing network of partners and customers.
Company data
Number of employees50-99
Foundation1992
Area of business- Laboratory Equipment
- Diagnostics